Journal
CELLS
Volume 10, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/cells10040842
Keywords
KRAS; cancer; signaling pathway; inhibitors
Categories
Funding
- MEST [2018R1D1A1B07043701, 2016R1D1A1B020 11142]
- National Research Foundation of Korea [2018R1D1A1B07043701] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
The KRAS oncogene is mutated in around 30% of human cancers, making it a key target for cancer research. Direct targeting of KRAS has proven to be ineffective, leading researchers to explore alternative approaches for drug development. This review provides an overview of KRAS structure, signaling pathways, challenges with existing inhibitors, and potential avenues for future drug development.
The KRAS oncogene is mutated in approximately similar to 30% of human cancers, and the targeting of KRAS has long been highlighted in many studies. Nevertheless, attempts to target KRAS directly have been ineffective. This review provides an overview of the structure of KRAS and its characteristic signaling pathways. Additionally, we examine the problems associated with currently available KRAS inhibitors and discuss promising avenues for drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
